tetano
Editor, Senior Moderator
Sci Rep
. 2025 Mar 6;15(1):7858.
doi: 10.1038/s41598-025-92254-8. Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
Yana Debie[SUP] 1 2 [/SUP], Irene Garcia-Fogeda[SUP] 3 [/SUP], Lander Willem[SUP] 4 [/SUP], Ella Roelant[SUP] 5 [/SUP], Lise Verbruggen[SUP] 1 [/SUP], Greetje Vanhoutte[SUP] 1 [/SUP], Lieselot Croes[SUP] 1 2 [/SUP], Christof Vulsteke[SUP] 2 6 [/SUP], Wim Demey[SUP] 7 [/SUP], Willem Lybaert[SUP] 8 [/SUP], Marianne Hanssens[SUP] 9 [/SUP], Alain Bols[SUP] 10 [/SUP], Johan Van Ongeval[SUP] 11 [/SUP], Ann De Becker[SUP] 12 [/SUP], Hilde Jansens[SUP] 13 [/SUP], Maria E Goossens[SUP] 14 [/SUP], Annelies Janssens[SUP] 1 2 [/SUP], Hans Prenen[SUP] 1 2 [/SUP], Sébastien Anguille[SUP] 1 15 [/SUP], Marc Peeters[SUP] 1 2 [/SUP], Peter A van Dam[SUP] 1 2 [/SUP], Niel Hens[SUP] 3 16 [/SUP], Steven Abrams[SUP] 4 16 [/SUP], Timon Vandamme[SUP] 17 18 [/SUP]
Affiliations
The level of protection against SARS-CoV-2 breakthrough infections conferred by the presence of anti-S1 SARS-CoV-2 antibodies (IgGs) in cancer patients is still understudied. This work examines the existence of an anti-S1 immunoglobulin G (IgG) -based correlate of protection (CoP) established by prospectively collected observational data about breakthrough infections with different SARS-CoV-2 variants in a large cohort study with vaccinated cancer patients. 760 cancer patients were longitudinally followed-up, starting before first vaccination until six months after second booster. Anti-S1 SARS-CoV-2 IgGs were quantified in serum samples (N = 2958) and breakthrough infections were monitored using questionnaires, routine COVID-19 testing and medical chart review. A Generalized Estimating Equations approach was used to model the binary infection status as endpoint in relation to anti-S1 IgG titers. It is observed that higher anti-S1 IgG titers correspond to a lower probability of breakthrough infection. For the early pandemic phase, a protective anti-S1 IgG titer above 20.42 BAU/mL was observed. However, with the emergence of the Omicron variant, higher anti-S1 IgG titers are required to be protective, but no clear CoP could be identified.
Keywords: Antibodies; Breakthrough infection; COVID-19; COVID-19 vaccination; Cancer patients; Correlate of protection; SARS-CoV-2.
. 2025 Mar 6;15(1):7858.
doi: 10.1038/s41598-025-92254-8. Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
Yana Debie[SUP] 1 2 [/SUP], Irene Garcia-Fogeda[SUP] 3 [/SUP], Lander Willem[SUP] 4 [/SUP], Ella Roelant[SUP] 5 [/SUP], Lise Verbruggen[SUP] 1 [/SUP], Greetje Vanhoutte[SUP] 1 [/SUP], Lieselot Croes[SUP] 1 2 [/SUP], Christof Vulsteke[SUP] 2 6 [/SUP], Wim Demey[SUP] 7 [/SUP], Willem Lybaert[SUP] 8 [/SUP], Marianne Hanssens[SUP] 9 [/SUP], Alain Bols[SUP] 10 [/SUP], Johan Van Ongeval[SUP] 11 [/SUP], Ann De Becker[SUP] 12 [/SUP], Hilde Jansens[SUP] 13 [/SUP], Maria E Goossens[SUP] 14 [/SUP], Annelies Janssens[SUP] 1 2 [/SUP], Hans Prenen[SUP] 1 2 [/SUP], Sébastien Anguille[SUP] 1 15 [/SUP], Marc Peeters[SUP] 1 2 [/SUP], Peter A van Dam[SUP] 1 2 [/SUP], Niel Hens[SUP] 3 16 [/SUP], Steven Abrams[SUP] 4 16 [/SUP], Timon Vandamme[SUP] 17 18 [/SUP]
Affiliations
- PMID: 40050359
- DOI: 10.1038/s41598-025-92254-8
The level of protection against SARS-CoV-2 breakthrough infections conferred by the presence of anti-S1 SARS-CoV-2 antibodies (IgGs) in cancer patients is still understudied. This work examines the existence of an anti-S1 immunoglobulin G (IgG) -based correlate of protection (CoP) established by prospectively collected observational data about breakthrough infections with different SARS-CoV-2 variants in a large cohort study with vaccinated cancer patients. 760 cancer patients were longitudinally followed-up, starting before first vaccination until six months after second booster. Anti-S1 SARS-CoV-2 IgGs were quantified in serum samples (N = 2958) and breakthrough infections were monitored using questionnaires, routine COVID-19 testing and medical chart review. A Generalized Estimating Equations approach was used to model the binary infection status as endpoint in relation to anti-S1 IgG titers. It is observed that higher anti-S1 IgG titers correspond to a lower probability of breakthrough infection. For the early pandemic phase, a protective anti-S1 IgG titer above 20.42 BAU/mL was observed. However, with the emergence of the Omicron variant, higher anti-S1 IgG titers are required to be protective, but no clear CoP could be identified.
Keywords: Antibodies; Breakthrough infection; COVID-19; COVID-19 vaccination; Cancer patients; Correlate of protection; SARS-CoV-2.